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Letter to the Editor:
Reproductive toxicology
Dear Sir,
The article published in Reproductive Toxicology entitled, In vitro and in vivo
reproduction toxicology of 12 monoaminergic reuptake inhibitors: Possible mechanism of
infrequent cardiovascular anomalies by Sloot et al. (1), presents the authors’ views in
determining the teratogenicity of a group of drugs utilizing whole embryo culture (WEC). The
authors used a well-described protocol for WEC utilizing five exposures ranging from 0-9
µg/mL to 0-100 µg/mL. For example, the five exposures for fluoxetine and paroxetine were 0
µg/mL, 0.3 µg/mL, 1 µg/mL, 3 µg/mL and 9 µg/mL and for mazindol and venlafaxine were 0
µg/mL, 10 µg/mL, 30 µg/mL, 60 µg/mL, and 100 µg/mL. The rat embryos were harvested at 9.5
days and grown for48 h at which time they were evaluated. The effects of the drugs were labeled
as embryotoxic, potentially teratogenic or teratogenic. It is appropriate to label pathologic
findings at 48 h as an embryotoxic effect. However you cannot label WEC pathologic findings as
potentially teratogenic unless you have data indicating that the embryo will survive to a viable

stage. Even more important you cannot label a chemical or drug as a teratogen unless you have
evidence that the embryo will survive the exposure during organogenesis as a malformed fetus.
Of course, some embryotoxins can cause the embryo to die with malformations before viability
is reached.
Sloot et al. all believe that they can demonstrate a teratogenic effect using WEC since the
authors labeled toxicological findings in the cultured embryos as evidence of a teratogenic effect.
While it is true that the authors of this paper used the term embryotoxicity and potential
teratogenicity in many places in the paper, they also describe paroxetine as a teratogen. Let me
quote from the paper the following two sentences. “In vitro, paroxetine and the positive control
retinol were the only compounds identified as a clear teratogen” (Abstract). In paragraph 3.1.2
under the Results section the following statement is also repeated. “Retinol and paroxetine were
the only two compounds identified as clear teratogens.” This conclusion is inappropriate because
the whole-animal teratology studies cited by authors did not result in teratogenesis (2,3) and the
exposures of paroxetine and fluoxetine in the WEC were greater than the exposures that occur in
the human with these drugs. Furthermore, these authors were unable to determine whether the
embryotoxic effects observed in WEC would result in lethality in vivo at these exposures. You
cannot utilize only the results of WEC to determine human teratogenic risks, unless the
investigator is certain that the exposure used in the WEC will not be lethal to the embryo in vivo.
The use of WEC can have the following positive goals or purposes.
(1) Investigators who have produced congenital malformation in pregnant animals such as
the rat after administering a drug or chemical can utilize whole embryo culture to
determine the mechanism of action of the teratogenic effect. The first publication using
the roller tube WEC technique was published in 1972 using teratogenic kidney antibodies
that were potent teratogens when injected into pregnant rats early in gestation (4-9). The

article describing these experiments was published by New and Brent and demonstrated
that the mechanism of embryotoxicity was interference with the yolk sac function and not
a direct effect on the embryo. Once teratogenicity was demonstrated in a whole-animal
model, exposures of yolk sac antibodies in WEC at the levels that occur in the circulation
of the whole-animal model permitted the investigators to determine the mechanism of
action (MOA). If WEC had been performed first, before there was evidence that
teratogenic antibody had an effect in a whole-animal study, the results would only
indicate that the antiserum was embryotoxic. We could not determine that it was
teratogenic, because we would not know the level of teratogenic antibody that occurs in
the whole animal in order to select the proper exposure in the embryo culture – and we
would not know whether the embryos would survive to term at these exposures.
(2) The second purpose of embryo culture is for screening. When a pharmaceutical company
prepares a new drug, there frequently are not large quantities of the drug available and,
therefore, the investigators cannot afford to utilize their restricted supply for wholeanimal teratology studies. Utilizing WEC to screen for the embryotoxicity of the
compound is perfectly appropriate; because it gives the investigators an idea at what
serum levels they can observe or not observe embryotoxic effects.
(3) WEC can be used to study many aspects of pharmacokinetics and determining the
putative teratogen. For example, Cyclophosphamide has been demonstrated to be
teratogenic in humans and rodents. However, the putative teratogen of
Cyclophosphamide is its metabolic product phosphoramide mustard, which is teratogenic
in vivo and in WEC while cyclophosphoramide is teratogenic in vivo but not in embryo
culture (10, 11).

(4) WEC can be used to study many aspects of normal embryonic development. You cannot
use embryo culture to determine whether an agent is going to be teratogenic in wholeanimal teratology study or in the human when you have no exposure data available in
either the human or the animal model at the time that you initiate the WEC. The reason
why utilizing WEC as the first project for determining teratogenicity and labeling an
agent as a teratogen is inappropriate (when you do not know whether it is teratogenic in a
whole-animal model) is because you have no idea whether the levels that produce an
embryotoxic effect in the WEC would be lethal to the embryo in the whole-animal
model. That is why the positive results of WEC results are described as an embryotoxic
effect. Teratogenicity infers that the abnormalities will be present at term in the liveborn
fetus or as a dead fetus later in pregnancy.
(5) WEC can be used to describe the actual developmental changes in the embryo that occur
during organogenesis when exposed to an embryotoxic agent.
If the authors had examined the package insert or the information available in the
Physician’s Desk Reference (12) they would have found the following information under the
section of Pharmacokinetics. When a human being is administered 30 mg of paroxetine that
reaches the steady state, the Cmax level for paroxetine is 61.7ng/mL. Following a single dose of
fluoxetine of 40 mg, the peak plasma concentration ranges between 15 and 55 ng/mL. In the
WEC experiments with paroxetine and fluoxetine the investigators used the following
concentrations; for paroxetine and fluoxetine; 0 µg/mL, 0.3 µg/mL, 1 µg/mL, 3 µg/mL and 9
µg/mL (Table 1 in the Sloot paper). The results of these embryo culture experiments with
paroxetine and fluoxetine are stated as follows, “Paroxetine at 3 µg/mL induced specific
malformations (fuse brachial bar, swollen posterior neuropore) without signs of embryotoxicity,
demonstrating a teratogenic potential. At higher concentration of 9 µg/mL, specific

malformations such as displaced/additional otic system and again brachial bar defects (fused or
swollen) were apparent. In the case of fluoxetine, one embryo showed irregular formed brachial
bars at 1 µg/mL without signs of embryotoxicity.”
In the embryo culture experiments using paroxetine the investigators had concentrations
of paroxetine of 0.3 µg/mL, 1 µg/mL, 3 µg/mL, and 9 µg/mL. This is respectively 5 times, 16
times, 48 times and 145 times the concentration that would be present in the human. Similarly
for fluoxetine, if the same concentration in the embryo culture of 0.3 µg/mL, 1 µg/mL, 3 µg/mL
and 9 µg/mL were used these concentrations are equal to 6 times, 20 times, 60 times and 160
times the clinical serum levels of fluoxetine.
It is interesting that the authors did not use the WEC that contained serum concentrations
that occur in humans who are treated with these medications. Furthermore, they demonstrated
quite clearly that they had to have very high levels of paroxetine and fluoxetine to produce any
effects in embryo culture. There is no drug or chemical that would not produce an embryotoxic
effect if the concentration were raised to very high levels. But teratogens have threshold
exposures below, which no deleterious effects are produced (13) and the authors demonstrated
that the NOAEL (no adverse effect level) for embryotoxicity was far above the usual human
exposures.
The most that we can conclude from WEC experiments if we have no evidence of
teratogenicity from animal studies (2,3) or inconsistent evidence from human epidemiology
studies is to indicate that a particular concentration of a drug or chemical is or is not
embryotoxic, since we do not know if the embryo will survive (14, 15). The most important
aspect of WEC is to utilize a serum concentration in the WEC that is similar to the serum level in
the exposed human or exposed animal model that has demonstrated teratogenesis.

Although the animal studies utilizing paroxetine and fluoxetine were negative (2,3), the
authors still attempted to produce a “teratogenic effect” in a WEC model.
Could the authors explain how a drug can be teratogenic in WEC but not in vivo in an
animal model? One of the reviewers of this Letter commented on Sloot et al.’s definition of
teratogenicity. “A basic principle of toxicological hazard identification is to identify lesions in
tissues following high doses of xenobiotic. A no adverse effect level is then defined in the
species concerned. Regulatory in vivo developmental toxicity studies are expected to show a
degree of toxicity at the highest dose levels (5). Sloot et al. were justified in taking a similar
approach in their in vitro experiments. The restrictive definition of teratogenicity used in this
paper.” i.e. “A specific malformation in the absence of effects on growth or development” is
valid within the context of the stated objectives of the experiment.” The problem with this
restrictive definition of teratogenicity is that it is not a scientifically valid definition and does not
apply to all teratogens.
You can have malformations caused by environmental agents that are not associated with
growth retardation and there may not even be an increase in fetal loss during development. You
can have exposures that produce growth retardation and death but do not result in live fetuses
with congenital malformations. Why did these investigators not expose the WEC to levels that
occur in the human when being treated with antidepressants. It is obvious that if Sloot et al.
would have found no effect at those levels the topic of teratogenic potential and teratogenicity
would not be relevant.
Another area of concern is the fact that the authors have described malformations of the
branchial arches as indications that paroxetine can produce congenital heart disease. They
provide no data to support this concept. While neural crest migration problems and other
hypothetical causes of congenital heart disease are plausible mechanisms, they provide no

evidence to support their hypothesis. Furthermore, they did not observe abnormalities of cardiac
development in the WEC, even with high concentrations of paroxetine.
The final paragraph in the author’s abstract states the following: “It is suggested that
observed specific malformations in vitro (e.g. branchial bars deformed, displaced or additional
otic system), not noted in any (historical) controls, may be early ontogenetic indicators for
infrequent CV-anomalies observed in vivo. Despite the low incidence of anomalies in vitro or in
vivo, they may yet be clinically relevant as in the case of paroxetine.”
Scientists should not draw conclusions from hypotheses. They must have objective
evidence in order to support their conclusions. These authors have no evidence that in their WEC
model that the cardiovascular malformations were produced at even highly toxic exposures.
Furthermore, they have no evidence that at lower exposures that are still much higher than would
be experienced by humans, that cardiovascular abnormalities or any malformations would be
observed in viable fetuses in later stage pregnancies.
1.

Summary
1.

WEC has many useful scientific purposes.

2.

You cannot utilize WEC to label a drug or chemical as a teratogen if the exposures
utilized will result in embryonic or fetal death in vivo.

3.

WEC can indicate that a drug or chemical is embryotoxic.

4.

If the exposure level for clinical use of a drug or environmental exposure of a
chemical is known, it should be used in WEC studies along with higher exposures
as well.

5.

You cannot predict that a drug is a cardiac teratogen from WEC when no cardiac
malformations are observed, as in this study. You can generate many hypotheses,

but unfortunately the hypotheses generated by Sloot et al. will not make cardiac
malformations appear in their WEC experiments.
6.

If whole-animal teratology studies are negative with clinically appropriate
exposures, WEC cannot provide information that will label the drug as a teratogen.
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